In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Neuro-focused start-up Biohaven nets $180mm in oversubscribed IPO on NYSE

Executive Summary

Orphan neurologic disease start-up Biohaven Pharmaceuticals Holding Co. Ltd. netted $180mm in its initial public offering on the New York Stock Exchange of 11.4mm shares (including the overallotment) at $17, above its anticipated range of $14-16 for 8.3mm shares.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Therapeutic Drug Monitoring
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

Advertisement
UsernamePublicRestriction

Register